Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine

BACKGROUND AND PURPOSE: The assessment of brain atrophy in a clinical routine is not performed routinely in multiple sclerosis. Our aim was to determine the feasibility of brain atrophy measurement and its association with disability progression in patients with MS followed in a clinical routine for 5 years. MATERIALS AND METHODS: A total of 1815 subjects, 1514 with MS and 137 with clinically isolated syndrome and 164 healthy individuals, were collected retrospectively. Of 11,794 MR imaging brain scans included in the analysis, 8423 MRIs were performed on a 3T, and 3371 MRIs, on a 1.5T scanner. All patients underwent 3D T1WI and T2-FLAIR examinations at all time points of the study. Whole-brain volume changes were measured by percentage brain volume change/normalized brain volume change using SIENA/SIENAX on 3D T1WI and percentage lateral ventricle volume change using NeuroSTREAM on T2-FLAIR. RESULTS: Percentage brain volume change failed in 36.7% of the subjects; percentage normalized brain volume change, in 19.2%; and percentage lateral ventricle volume change, in 3.3% because of protocol changes, poor scan quality, artifacts, and anatomic variations. Annualized brain volume changes were significantly different between those with MS and healthy individuals for percentage brain volume change (P < .001), percentage normalized brain volume change (P = .002), and percentage lateral ventricle volume change (P = .01). In patients with MS, mixed-effects model analysis showed that disability progression was associated with a 21.9% annualized decrease in percentage brain volume change (P < .001) and normalized brain volume (P = .002) and a 33% increase in lateral ventricle volume (P = .004). CONCLUSIONS: All brain volume measures differentiated MS and healthy individuals and were associated with disability progression, but the lateral ventricle volume assessment was the most feasible.

[1]  M. Dwyer,et al.  Establishing pathological cut-offs for lateral ventricular volume expansion rates , 2018, NeuroImage: Clinical.

[2]  Robert Zivadinov,et al.  Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study , 2017, CNS Drugs.

[3]  M. Dwyer,et al.  Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS , 2017, American Journal of Neuroradiology.

[4]  L. Kappos,et al.  Teriflunomide slows BVL in relapsing MS , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[5]  D. Ramasamy,et al.  Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis , 2017, NeuroImage: Clinical.

[6]  Deborah Pareto,et al.  Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects. , 2017, Neuroimaging clinics of North America.

[7]  M. Battaglini,et al.  Brain MRI atrophy quantification in MS , 2017, Neurology.

[8]  M. Dwyer,et al.  Brain atrophy measurements should be used to guide therapy monitoring in MS – YES , 2016, Multiple sclerosis.

[9]  R. Benedict,et al.  Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine , 2016, Expert review of neurotherapeutics.

[10]  M. Sormani,et al.  The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis , 2016, PloS one.

[11]  D. Ramasamy,et al.  A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients , 2016, Multiple sclerosis.

[12]  A. Dibernardo,et al.  The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis , 2015, Journal of the Neurological Sciences.

[13]  G. Tsivgoulis,et al.  The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis , 2015, Therapeutic advances in neurological disorders.

[14]  M. Battaglini,et al.  Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  G. Tsivgoulis,et al.  The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis , 2015, PloS one.

[16]  D. Ramasamy,et al.  Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome , 2014, Journal of Neurology.

[17]  Olivier Gout,et al.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.

[18]  H. Wiendl,et al.  Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.

[19]  D. Arnold,et al.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.

[20]  M. Dwyer,et al.  Thalamic atrophy is associated with development of clinically definite multiple sclerosis. , 2013, Radiology.

[21]  Mark Jenkinson,et al.  The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis , 2012, Human brain mapping.

[22]  M. Battaglini,et al.  Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.

[23]  D. Louis Collins,et al.  Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change , 2010, NeuroImage.

[24]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[25]  Rohit Bakshi,et al.  The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.

[26]  F. Barkhof,et al.  Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. , 2002, Archives of neurology.

[27]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[28]  Nick C Fox,et al.  Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[29]  Gianpaolo Donzelli,et al.  Catch-Up Growth in Short-at-Birth NICU Graduates , 2000, Hormone Research in Paediatrics.

[30]  Nick C Fox,et al.  Detection of ventricular enlargement in patients at the earliest clinical stage of MS , 2000, Neurology.

[31]  R. Herndon,et al.  A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.